Purple Biotech (PPBT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.44 (-6.80%), Market cap $0.00B, P/E ratio 0.00, 52-week low–high $0.44 ~ $5.02.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or met
Financial statements, price targets, institutional (13F) holdings and related news for Purple Biotech are updated in real time on BlackAll Trade.
Purple Biotech trades at $1.44 (-6.80%). Real-time quotes and charts are available on BlackAll Trade.
Purple Biotech has a market cap of about $0.00B. Its P/E ratio is 0.00.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline incl